Hazte socio de la SAMFyC

Última publicación SAMFyC: Actualización en MF y APS

 

AULA VIRTUAL SAMFyC

Aula de formación virtual de SAMFyC

SAMFyC CONGRESOS

Historico de Comunicaciones
presentadas a los Congresos
Andaluces de MFyC (SAMFyC), desde 2008.


* * * * * * * * * * * * * * * * * * * * * * * * *

Información Socios

Ofertas de Trabajo
Ofertas de Trabajo SOCIOS SAMFYC

¡Actualiza tus datos!
Actualiza tus datos

 

Buscador de Contenidos

Sociedades Federadas

Medicina Familiar y Comunitaria

Sociedades Científicas de Medicina Familiar y Comunitaria

Enlaces de Interés

Consulte Nuestros Enlaces.
Enlaces de Interés

Acceso Socios



Buscador de publicaciones externas y alertas bibliográficas

Junio 2013 PDF Imprimir E-mail
Viernes, 05 de Julio de 2013 00:00

Volver

SELECCIÓN DE REFERENCIAS BIBLIOGRÁFICAS DE LO PUBLICADO EN RELACIÓN CON ATENCIÓN PRIMARIA

Selección realizada por Antonio Manteca González

Tierney MJ, Pageler NM, Kahana M, Pantaleoni JL, Longhurst CA. Medical education in the Electronic Medical Record (EMR) era: benefits, challenges, and future directions. Acad Med. 2013; 88:748-752 [R,I]

23619078             R/C

FORMACIÓN MÉDICA EN LA ÉPOCA DE LA HISTORIA CLÍNICA ELECTRÓNICA: BENEFICIOS, RETOS Y DIRECCIONES FUTURAS

 

Hughes MC, Williams GM, Baker P, Green AC. Sunscreen and prevention of skin aging: a randomized trial. Ann Intern Med. 2013; 158:781-790 [EC,I]

23732711             R/C

PANTALLA SOLAR Y PREVENCIÓN DEL ENVEJECIMIENTO DE LA PIEL: ENSAYO ALEATORIZADO

 

Chou R, Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. Ann Intern Med. 2013; 158:807-820 [M,II]

23732714             R/C

PRUEBAS SANGUÍNEAS PARA DIAGNOSTICAR FIBROSIS O CIRROSIS EN PACIENTES CON INFECCIÓN CRÓNICA POR EL VIRUS DE LA HEPATITIS C: REVISIÓN SISTEMÁTICA

 

Stevens PE, Levin A; Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members*. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013; 158:825-830 [M,II]

23732715             R/C

EVALUACIÓN Y MANEJO DE LA ENFERMEDAD RENAL CRÓNICA: SINOPSIS DE LA ENFERMEDAD RENAL: GUÍA DE PRÁCTICA CLÍNICA 2012 PARA MEJORAR LOS RESULTADOS MUNDIALES

 

Hayes JH, Ollendorf DA, Pearson SD, Barry MJ, Kantoff PW, Lee PA, et al. Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis. Ann Intern Med. 2013; 158:853-860 [CE,II]

23778902             R/C

OBSERVACIÓN FRENTE A TRATAMIENTO DE INICIO EN HOMBRES CON CÁNCER DE PRÓSTATA LOCALIZADO DE BAJO RIESGO: ANÁLISIS DE RENTABILIDAD

 

Mahaffey KW, Wojdyla D, Hankey GJ, White HD, Nessel CC, Piccini JP, et al. Clinical outcomes with rivaroxaban in patients transitioned from vitamin k antagonist therapy: a subgroup analysis of a randomized trial. Ann Intern Med. 2013; 158:861-868 [EC,II]

23778903             R/C

RESULTADOS CLÍNICOS CON RIVAROXABAN EN PACIENTES EN TRANSICIÓN DESDE TERAPIA CON ANTAGONISTAS DE LA VITAMINA K: ANÁLISIS DE SUBGRUPO DE UN ENSAYO ALEATORIZADO

 

Patel AM, Shariff S, Bailey DG, Juurlink DN, Gandhi S, Mamdani M, et al. Statin toxicity from macrolide antibiotic coprescription: a population-based cohort study. Ann Intern Med. 2013; 158:869-876 [S,II]

23778904             R/C

TOXICIDAD CON ESTATINAS PRESCRITAS JUNTO CON ANTIBIÓTICOS MACRÓLIDOS: ESTUDIO DE COHORTE POBLACIONAL

 

Arnedillo A. El infradiagnóstico de la enfermedad pulmonar obstructiva crónica en mujeres. ¿Otra tarea pendiente? Arch Bronconeumol. 2013; 49:221-222 [AO,I]

23562408

EL INFRADIAGNÓSTICO DE LA ENFERMEDAD PULMONAR OBSTRUCTIVA CRÓNICA EN MUJERES. ¿OTRA TAREA PENDIENTE?

 

Ancochea J, Miravitlles M, García-Río F, Muñoz L, Sánchez G, Sobradillo V, et al. Infradiagnóstico de la enfermedad pulmonar obstructiva crónica en mujeres: cuantificación del problema, determinantes y propuestas de acción. Arch Bronconeumol. 2013; 49:223-229 [T,I]

23317767            R/C

INFRADIAGNÓSTICO DE LA ENFERMEDAD PULMONAR OBSTRUCTIVA CRÓNICA EN MUJERES: CUANTIFICACIÓN DEL PROBLEMA, DETERMINANTES Y PROPUESTAS DE ACCIÓN

 

Julián-Jiménez A, Palomo MJ, Parejo R, Laín-Terés N, Cuena-Boy R, Lozano-Ancín A. Mejora del manejo de la neumonía adquirida en la comunidad en el servicio de urgencias. Arch Bronconeumol. 2013; 49:230-240 [QE,I]

23477946             R/C

MEJORA DEL MANEJO DE LA NEUMONÍA ADQUIRIDA EN LA COMUNIDAD EN EL SERVICIO DE URGENCIAS

 

Meléndez L, González C, Alvarez-Dardet C. Los funcionales a examen: ¿alimentos al servicio de la salud o nuevo negocio para la industria alimentaria? Aten Primaria. 2013; 45:287-289 [AO,I]

23481127

LOS FUNCIONALES A EXAMEN: ¿ALIMENTOS AL SERVICIO DE LA SALUD O NUEVO NEGOCIO PARA LA INDUSTRIA ALIMENTARIA?

 

Legido-Quigley H, Otero L, Parra Dl, Alvarez-Dardet C, Martin-Moreno JM, McKee M. Will austerity cuts dismantle the Spanish healthcare system? BMJ. 2013; 346:f2363 [AO,I]

23766463

¿VAN A DESMANTELAR LOS RECORTES EL SISTEMA DE ATENCIÓN SANITARIA ESPAÑOL?

 

Gallo JJ, Morales KH, Bogner HR, Raue PJ, Zee J, Bruce ML, et al. Long term effect of depression care management on mortality in older adults: follow-up of cluster randomized clinical trial in primary care. BMJ. 2013; 346:f2570 [EC,I]

23738992             R/C

EFECTO A LARGO PLAZO DE LA ATENCIÓN A LA DEPRESIÓN EN LOS ANCIANOS: SEGUIMIENTO DE UN ENSAYO CLÍNICO ALEATORIZADO AGRUPADO EN ATENCIÓN PRIMARIA

 

Pharoah PD, Sewell B, Fitzsimmons D, Bennett HS, Pashayan N. Cost effectiveness of the NHS breast screening programme: life table model. BMJ. 2013; 346:f2618 [CE,I]

23661112             R/C

RENTABILIDAD DEL PROGRAMA DE CRIBAJE DE CÁNCER DE MAMA DEL NHS: MODELO DE TABLA DE SUPERVIVENCIA

 

Parry SW, Finch T, Deary V. How should we manage fear of falling in older adults living in the community? BMJ. 2013; 346:f2933 [R,I]

23714190

¿CÓMO DEBERÍAMOS DE MANEJAR EL MIEDO A LAS CAÍDAS EN LOS ANCIANOS QUE VIVEN EN LA COMUNIDAD?

 

Freynhagen R, Geisslinger G, Schug SA. Opioids for chronic non-cancer pain. BMJ. 2013; 346:f2937 [R,I]

23719636

OPIOIDES EN EL DOLOR CRÓNICO NO ONCOLÓGICO

 

Sohal AH, James-Hanman D. Responding to intimate partner and sexual violence against women. BMJ. 2013; 346:f3100 [AO,I]

23788378

RESPONDER A LA VIOLENCIA DE PAREJA Y A LA VIOLENCIA SEXUAL CONTRA LA MUJER

 

Huupponen R, Viikari J. Statins and the risk of developing diabetes. BMJ. 2013; 346:f3156 [AO,I]

23709567

ESTATINAS Y RIESGO DE DESARROLLAR DIABETES

 

Lumsden MA, Gebbie A, Holland C. Managing unscheduled bleeding in non-pregnant premenopausal women. BMJ. 2013; 346:f3251 [R,I]

23737266

MANEJAR EL SANGRADO FUERA DE LA REGLA EN MUJERES PREMENOPÁUSICAS NO EMBARAZADAS

 

Robinson D, Garmo H, Bill-Axelson A, Mucci L, Holmberg L, Stattin P. Use of 5a-reductase inhibitors for lower urinary tract symptoms and risk of prostate cancer in Swedish men: nationwide, population based case-control study. BMJ. 2013; 346:f3406 [CC,I]

23778271             R/C

USO DE INHIBIDORES DE LA 5 ALFA REDUCTASA EN LOS SÍNTOMAS DE VÍAS URINARIAS BAJAS Y RIESGO DE CÁNCER DE PRÓSTATA EN HOMBRES SUECOS: ESTUDIO CASO-CONTROL POBLACIONAL DE ÁMBITO NACIONAL

 

Thachil J, Fitzmaurice D. Thrombocytopenia in an adult. BMJ. 2013; 346:f3407 [R,I]

23751903

TROMBOCITOPENIA EN UN ADULTO

 

Haider BA, Olofin I, Wang M, Spiegelman D, Ezzati M, Fawzi WW; Nutrition Impact Model Study Group (anaemia). Anaemia, prenatal iron use, and risk of adverse pregnancy outcomes: systematic review and meta-analysis. BMJ. 2013; 346:f3443 [M,II]

23794316            R/C

ANEMIA, USO DE HIERRO PRENATAL Y RIESGO DE RESULTADOS ADVERSOS EN EL EMBARAZO: REVISIÓN SISTEMÁTICA Y METAANÁLISIS

 

King A, Azuara-Blanco A, Tuulonen A. Glaucoma. BMJ. 2013; 346:f3518 [R,I]

23757737

GLAUCOMA

 

Dworzynski K, Ritchie G, Fenu E, Macdermott K, Playford ED; Guideline Development Group. Rehabilitation after stroke: summary of NICE guidance. BMJ. 2013; 346:f3615 [M,II]

23760965

REHABILITACIÓN TRAS EL ICTUS: RESUMEN DE LA GUÍA NICE

 

Gale E. Incretin therapy: should adverse consequences have been anticipated? BMJ. 2013; 346:f3617 [AO,I]

23751905

TERAPIA CON INCRETINAS: ¿SE DEBERÍAN HABER PREVISTO LAS CONSECUENCIAS ADVERSAS?

 

Montori VM. Helping patients make sense of the risks of taking GLP-1 agonists. BMJ. 2013; 346:f3692 [AO,I]

23751906

AYUDAR A LOS PACIENTES A SER CONSCIENTES DE LOS RIESGOS DE TOMAR AGONISTAS DE GLP-1

 

Green R, Cornelsen L, Dangour AD, Turner R, Shankar B, Mazzocchi M, et al. The effect of rising food prices on food consumption: systematic review with meta-regression. BMJ. 2013; 346:f3703 [M,II]

23775799             R/C

EFECTO DEL AUMENTO DE PRECIOS DE LOS ALIMENTOS SOBRE EL CONSUMO DE COMIDA: REVISIÓN SISTEMÁTICA CON METARREGRESIÓN

 

Bradley A, Sheridan P. Atrial fibrillation. BMJ. 2013; 346:f3719 [R,I]

23775800

FIBRILACIÓN AURICULAR

 

Arie S. Has austerity brought Europe to the brink of a health disaster? BMJ. 2013; 346:f3773 [AO,I]

23778577

¿HA LLEVADO LA AUSTERIDAD AL BORDE DE UN DESASTRE SANITARIO A EUROPA?

 

Haggerty JL, Lévesque JF, Hogg W, Wong S. The strength of primary care systems. BMJ. 2013; 346:f3777 [AO,I]

23766466

FORTALEZA DE LOS SISTEMAS DE ATENCIÓN PRIMARIA

 

Goldacre B, Spiegelhalter D. Bicycle helmets and the law. BMJ. 2013; 346:f3817 [AO,I]

23760970

LOS CASCOS DE BICICLETA Y LA LEY

 

Evans DG, Graham J, O´Connell S, Arnold S, Fitzsimmons D. Familial breast cancer: summary of updated NICE guidance. BMJ. 2013; 346:f3829 [M,II]

23801680

CÁNCER DE MAMA FAMILIAR: RESUMEN DE LA GUÍA NICE ACTUALIZADA

 

Sun X, Guyatt GH. Interventions to enhance self management support. BMJ. 2013; 346:f3949 [AO,I]

23783357

INTERVENCIONES PARA REFORZAR EL APOYO AL AUTOMANEJO

 

Sokol DK. Patients we don't like. BMJ. 2013; 346:f3956 [AO,I]

23783359

PACIENTES QUE NO NOS GUSTAN

 

Moynihan R. Australia moves closer to full disclosure of drug company payments to doctors. BMJ. 2013; 346:f3960 [AO,I]

23783360

AUSTRALIA SE ACERCA CADA VEZ MÁS A LA DIVULGACIÓN COMPLETA DE LOS PAGOS DE LAS COMPAÑÍAS FARMACÉUTICAS A LOS MÉDICOS

 

SaltmanRB, Cahn Z. Restructuring health systems for an era of prolonged austerity: an essay by Richard B Saltman and Zachary Cahn. BMJ. 2013; 346:f3972  [R,II]

REESTRUCTURAR LOS SISTEMAS SANITARIOS PARA UNA ÉPOCA DE AUSTERIDAD PROLONGADA

 

Godlee F. In praise of informed scepticism. BMJ. 2013; 346:f3980  [AO,I]

ELOGIO DEL ESCEPTICISMO INFORMADO

 

Why we can't trust clinical guidelines. BMJ. 2013; 346:f3998 [AO,I]

23783038

POR QUÉ NO NOS PODEMOS FIAR DE LAS GUÍAS CLÍNICAS

 

Davies E. Can you trust your clinical guidelines? BMJ. 2013; 346:f4003 [AO,I]

¿PUEDE USTED CONFIAR EN SUS GUÍAS CLÍNICAS?

 

Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting ß2 agonist: observational matched cohort study (PATHOS). BMJ. 2013; 346:f4037 [S,II]

23788471

MORTALIDAD POR NEUMONÍA Y RELACIONADA CON LA NEUMONÍA EN PACIENTES CON EPOC TRATADOS CON COMBINACIONES FIJAS DE CORTICOIDES INHALADOS Y AGONISTAS BETA2 DE ACCIÓN PROLONGADA (LABA): ESTUDIO OBSERVACIONAL DE COHORTES EMPAREJADAS

 

Bland RC, Streiner DL. Why screening for depression in primary care is impractical. CMAJ. 2013; 185:753-754 [AO,I]

23670151

POR QUÉ NO ES PRÁCTICO EL CRIBAJE DE LA DEPRESIÓN EN ATENCIÓN PRIMARIA

 

Kivimäki M, Nyberg ST, Fransson EI, Heikkilä K, Alfredsson L, Casini A, et al; IPD-Work Consortium. Associations of job strain and lifestyle risk factors with risk of coronary artery disease: a meta-analysis of individual participant data. CMAJ. 2013; 185:763-769 [M,II]

23670152            R/C

ASOCIACIONES DEL ESFUERZO LABORAL Y LOS FACTORES DE RIESGO DEL TIPO DE VIDA CON EL RIESGO DE ENFERMEDAD ARTERIAL CORONARIA: METAANÁLISIS DE DATOS DE PARTICIPANTES INDIVIDUALES

 

Canadian Task Force on Preventive Health Care, Joffres M, Jaramillo A, Dickinson J, Lewin G, Pottie K, Shaw E, et al. Recommendations on screening for depression in adults. CMAJ. 2013; 185:775-782 [M,II]

23670157

RECOMENDACIONES SOBRE EL CRIBAJE DE LA DEPRESIÓN EN ADULTOS

 

Gallego P, Vilchez JA, Lane DA. Apixaban compared with warfarin for stroke prevention in atrial fibrillation: implications of time in therapeutic range. Circulation. 2013; 127:2163-2165 [AO,I]

23640972

APIXABAN COMPARADO CON WARFARINA EN LA PREVENCIÓN DEL ICTUS EN LA FIBRILACIÓN AURICULAR: IMPLICACIONES DEL TIEMPO EN RANGO TERAPÉUTICO

 

Wallentin L, Lopes RD, Hanna M, Thomas L, Hellkamp A, Nepal S, et al; Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Investigators. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation. 2013; 127:2166-2176 [EC,II]

23640971             R/C

EFICACIA Y SEGURIDAD DEL APIXABAN COMPARADO CON WARFARINA A DIFERENTES NIVELES DE CONTROL DE INR PREDICHO PARA LA PREVENCIÓN DEL ICTUS EN LA FIBRILACIÓN AURICULAR

 

Zeller T, Trenk D. Cilostazol: the "Poor man's" replacement of drug-eluting stents and balloons? Circulation. 2013; 127:2261-2263 [AO,I]

23652862

CILOSTAZOL: ¿EL SUSTITUTIVO DEL "POBRE" DE LOS STENT LIBERADORES DE FÁRMACO Y DE LOS CATÉTERES DE BALÓN?

 

Kawahara T, Nishikawa M, Kawahara C, Inazu T, Sakai K, Suzuki G. Atorvastatin, etidronate, or both in patients at high risk for atherosclerotic aortic plaques: a randomized, controlled trial. Circulation. 2013; 127:2327-2335 [EC,I]

23658438             R/C

ATORVASTATINA, ETIDRONATO O AMBOS EN PACIENTES CON RIESGO ELEVADO DE PLACAS AÓRTICAS ATEROSCLERÓTICAS: ENSAYO CONTROLADO ALEATORIZADO

 

Raj SR. Postural Tachycardia Syndrome (POTS). Circulation. 2013; 127:2336-2342 [R,I]

23753844

SÍNDROME DE TAQUICARDIA POSTURAL

 

Vardas PE, Simantirakis EN, Kanoupakis EM. New developments in cardiac pacemakers. Circulation. 2013; 127:2343-2350 [R,I]

23753845

NUEVOS DESARROLLOS EN MARCAPASOS CARDIACOS

 

Levine GN, Allen K, Braun LT, Christian HE, Friedmann E, Taubert KA, et al; American Heart Association Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing. Pet ownership and cardiovascular risk: a scientific statement from the American Heart Association. Circulation. 2013; 127:2353-2363 [M,II]

23661721

POSESIÓN DE ANIMALES DOMÉSTICOS Y RIESGO CARDIOVASCULAR: DECLARACIÓN CIENTÍFICA DE LA AHA

 

2007 WRITING COMMITTEE MEMBERS; Presidents and Staff; American College of Cardiology Foundation; American College of Cardiology Foundation/American Heart Association; American Heart Association. 2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013; 127:e663-e828 [M,II]

23630129

ACTUALIZACIÓN FOCALIZADA DE 2012 LA ACCF/AHA INCORPORADA A LAS GUÍAS 2007 DE ACCF/AHA PARA EL MANEJO DE PACIENTES CON ANGINA INESTABLE/INFARTO DE MIOCARDIO SIN ELEVACIÓN DE ST: INFORME DEL GRUPO DE TRABAJO SOBRE GUÍAS DE PRÁCTICA CLÍNICA DE LA ACCF/AHA

 

Sinkeler SJ, Kwakernaak AJ, Bakker SJ, Shahinfar S, Esmatjes E, de Zeeuw D, et al. Creatinine excretion rate and mortality in type 2 diabetes and nephropathy. Diabetes Care. 2013; 36:1489-1494 [EC,I]

23300289             R/C

TASA DE EXCRECIÓN DE CREATININA Y MORTALIDAD EN LA DIABETES TIPO 2 Y NEFROPATÍA

 

Beverly EA, Fitzgerald S, Sitnikov L, Ganda OP, Caballero AE, Weinger K. Do older adults aged 60-75 years benefit from diabetes behavioral interventions? Diabetes Care. 2013; 36:1501-1506 [QE,I]

23315603            R/C

¿SE BENEFICIAN LOS ADULTOS DE ENTRE 60 Y 75 AÑOS DE LAS INTERVENCIONES CONDUCTUALES EN LA DIABETES?

 

Harris Nwanyanwu K, Talwar N, Gardner TW, Wrobel JS, Herman WH, Stein JD. Predicting development of proliferative diabetic retinopathy. Diabetes Care. 2013; 36:1562-1568 [S,I]

23275374             R/C

PREDECIR EL DESARROLLO DE LA RETINOPATÍA DIABÉTICA PROLIFERATIVA

 

Lacroix M, Battista MC, Doyon M, Ménard J, Ardilouze JL, Perron P, et al. Lower adiponectin levels at first trimester of pregnancy are associated with increased insulin resistance and higher risk of developing gestational diabetes mellitus. Diabetes Care. 2013; 36:1577-1583 [T,I]

23300287             R/C

NIVELES MENORES DE ADIPONECTINA EN EL PRIMER TRIMESTRE DE EMBARAZO SE ASOCIAN CON MAYOR RESISTENCIA A LA INSULINA Y MAYOR RIESGO DE DESARROLLAR DIABETES MELLITUS GESTACIONAL

 

Ma WY, Yang CY, Shih SR, Hsieh HJ, Hung CS, Chiu FC, et al. Measurement of waist circumference: midabdominal or iliac crest? Diabetes Care. 2013; 36:1660-1666 [S,I]

23275359             R/C

MEDIDA DEL PERÍMETRO ABDOMINAL: ¿A MITAD DEL ABDOMEN O EN LAS CRESTAS ILÍACAS?

 

Casado-Arroyo R, Sostres C, Lanas A. Optimizing the use of aspirin for cardiovascular prevention. Drugs. 2013; 73:803-814 [R,I]

23677803             R/C

OPTIMIZAR EL USO DE LA ASPIRINA EN LA PREVENCIÓN CARDIOVASCULAR

 

Kate V, Kalayarasan R, Ananthakrishnan N. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a systematic review of recent evidence. Drugs. 2013; 73:815-824 [M,II]

23625272             R/C

TERAPIA SECUENCIAL FRENTE A TERAPIA TRIPLE ESTÁNDAR PARA LA ERRADICACIÓN DEL HELICOBACTER PYLORI: REVISIÓN SISTEMÁTICA DE LAS EVIDENCIAS RECIENTES

 

Keating GM. Apixaban: a review of its use for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Drugs. 2013; 73:825-843 [R,I]

23677804             R/C

APIXABAN: REVISIÓN DE SU USO PARA REDUCIR EL RIESGO DE ICTUS Y EL EMBOLISMO SISTÉMICO EN PACIENTES CON FIBRILACIÓN AURICULAR NO VALVULAR

 

Collet JP, Montalescot G. Any room left for new antiplatelet agents in acute coronary syndrome? Eur Heart J. 2013; 34:1699-1701 [AO,I]

23585493

¿QUEDA SITIO PARA LOS NUEVOS AGENTES ANTIPLAQUETARIOS EN EL SÍNDROME AGUDO CORONARIO?

 

Meier P, Lansky AJ. Optimal duration of clopidogrel therapy: the shorter the longer? Eur Heart J. 2013; 34:1705-1707 [AO,I]

23136400

DURACIÓN ÓPTIMA DEL TRATAMIENTO CON CLOPIDOGREL: ¿MIENTRAS MÁS CORTO, MÁS LARGO?

 

Agewall S, Cattaneo M, Collet JP, Andreotti F, Lip GY, Verheugt FW, et al; ESC Working Group on Cardiovascular Pharmacology and Drug Therapy and ESC Working Group on Thrombosis. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J. 2013; 34:1708-1713 [M,II]

23425521

DOCUMENTO DE POSICIÓN DE LOS EXPERTOS SOBRE EL USO DE LOS INHIBIDORES DE LA BOMBA DE PROTONES EN PACIENTES CON ENFERMEDAD CARDIOVASCULAR Y TRATAMIENTO ANTITROMBÓTICO

 

Wanner C. Chronic kidney disease and statin therapy: to treat or not to treat? Eur Heart J. 2013; 34:1772-1774 [AO,I]

23604421

ENFERMEDAD RENAL CRÓNICA Y TERAPIA CON ESTATINAS: ¿TRATAR O NO TRATAR?

 

Ray KK. Statin treatment and the risk of recurrent pulmonary embolism. Eur Heart J. 2013; 34:1775-1777 [AO,I]

23585491

TRATAMIENTO CON ESTATINAS Y RIESGO DE EMBOLISMO PULMONAR RECURRENTE

 

Thorsson B, Steingrimsdottir L, Halldorsdottir S, Andersen K, Sigurdsson G, Aspelund T, et al. Changes in total cholesterol levels in Western societies are not related to statin, but rather dietary factors: the example of the Icelandic population. Eur Heart J. 2013; 34:1778-1782 [AO,II]

23209261

LOS CAMBIOS EN LOS NIVELES DE COLESTEROL TOTAL EN LAS SOCIEDADES OCCIDENTALES NO ESTÁN RELACIONADOS CON LAS ESTATINAS, SINO MÁS BIEN CON FACTORES DIETÉTICOS: EL EJEMPLO DE LA POBLACIÓN ISLANDESA

 

Norata GD, Ballantyne CM, Catapano AL. New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs. Eur Heart J. 2013; 34:1783-1789 [R,I]

23509227             R/C

NUEVOS PRINCIPIOS TERAPÉUTICOS EN LAS DISLIPEMIAS: ENFOQUE SOBRE LOS FÁRMACOS QUE BAJAN EL LDL Y LA LP(A)

 

Schuler G, Adams V, Goto Y. Role of exercise in the prevention of cardiovascular disease: results, mechanisms, and new perspectives. Eur Heart J. 2013; 34:1790-1799 [R,I]

23569199             R/C

PAPEL DEL EJERCICIO EN LA PREVENCIÓN DE LA ENFERMEDAD CARDIOVASCULAR: RESULTADOS, MECANISMOS Y NUEVAS PERSPECTIVAS

 

Yates JE. Intern evaluation strategies in family medicine residency education: what is-and is not-being done. Fam Med. 2013; 45:387-391 [T,I]

23743938             R/C

ESTRATEGIAS DE EVALUACIÓN INTERNA EN LA FORMACIÓN EN LA RESIDENCIA EN MEDICINA DE FAMILIA: QUÉ SE ESTÁ HACIENDO Y QUÉ NO

 

Pensa M, Frew P, Gelmon SB. Integrating improvement learning into a family medicine residency curriculum. Fam Med. 2013; 45:409-416 [T,I]

23743941             R/C

INTEGRAR LA MEJORÍA DEL APRENDIZAJE EN EL CURRÍCULO DE UNA RESIDENCIA EN MEDICINA DE FAMILIA

 

 

Nderitu P, Doos L, Jones PW, Davies SJ, Kadam UT. Non-steroidal anti-inflammatory drugs and chronic kidney disease progression: a systematic review. Fam Pract. 2013; 30:247-255 [M,I]

23302818             R/C

AINE Y PROGRESIÓN DE LA ENFERMEDAD RENAL CRÓNICA: REVISIÓN SISTEMÁTICA

 

Huntley AL, Thomas R, Mann M, Huws D, Elwyn G, Paranjothy S, et al. Is case management effective in reducing the risk of unplanned hospital admissions for older people? A systematic review and meta-analysis. Fam Pract. 2013; 30:266-275 [M,I]

23315222             R/C

¿ES EFECTIVA LA GESTIÓN DE CASOS PARA REDUCIR EL RIESGO DE INGRESOS HOSPITALARIOS NO PLANIFICADOS DE ANCIANOS? REVISIÓN SISTEMÁTICA Y METAANÁLISIS

 

Marks A, Macleod C, McAteer A, Murchie P, Fluck N, Smith WC, et al. Chronic kidney disease, a useful trigger for proactive primary care? Mortality results from a large UK cohort. Fam Pract. 2013; 30:282-289 [S,I]

23248235             R/C

ENFERMEDAD RENAL CRÓNICA ¿DESENCADENANTE ÚTIL DE UNA ATENCIÓN PRIMARIA PROACTIVA? RESULTADOS DE MORTALIDAD DE UNA GRAN COHORTE EN EL RU

 

Kendall M, Mason B, Momen N, Barclay S, Munday D, Lovick R, et al. Proactive cancer care in primary care: a mixed-methods study. Proactive cancer care in primary care: a mixed-methods study. Fam Pract. 2013; 30:302-312 [R,C,I]

23382502             R/C

ATENCIÓN PROACTIVA AL CÁNCER EN ATENCIÓN PRIMARIA: ESTUDIO DE MÉTODOS MIXTOS

 

Koper D, Kamenski G, Flamm M, Böhmdorfer B, Sönnichsen A. Frequency of medication errors in primary care patients with polypharmacy. Fam Pract. 2013; 30:313-319 [T,I]

23132894             R/C

FRECUENCIA DE ERRORES DE MEDICACIÓN EN PACIENTES DE ATENCIÓN PRIMARIA CON POLIFARMACIA

 

Greiver M, Williamson T, Bennett TL, Drummond N, Savage C, Aliarzadeh B, et al; Canadian Primary Care Sentinel Surveillance Network (CPCSSN). Developing a method to estimate practice denominators for a national Canadian electronic medical record database. Fam Pract. 2013; 30:347-354 [T,I]

23307818             R/C

DESARROLLAR UN MÉTODO PARA CALCULAR DENOMINADORES PRÁCTICOS PARA UNA BASE DE DATOS DE REGISTROS MÉDICOS ELECTRÓNICOS NACIONAL CANADIENSE

 

Leuppi JD, Schuetz P, Bingisser R, Bodmer M, Briel M, Drescher T, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA. 2013; 309:2223-2231 [EC,II]

23695200             R/C

TRATAMIENTO CORTICOIDEO A CORTO PLAZO FRENTE A CONVENCIONAL EN LAS EXACERBACIONES AGUDAS DE LA EPOC: ENSAYO CLÍNICO ALEATORIZADO REDUCE

 

Sin DD, Park HY. Steroids for treatment of COPD exacerbations: less is clearly more. JAMA. 2013; 309:2272-2273 [AO,I]

23695265

CORTICOIDES EN EL TRATAMIENTO DE LAS EXACERBACIONES DE LA EPOC: MENOS ES CLARAMENTE MÁS

 

Wolfe BM, Purnell JQ, Belle SH. Treating diabetes with surgery. JAMA. 2013; 309:2274-2275 [AO,I]

23736737

TRATAR LA DIABETES CON CIRUGÍA

 

White A, Danis M. Enhancing patient-centered communication and collaboration by using the electronic health record in the examination room. JAMA. 2013; 309:2327-2328 [R,I]

23757080

REFORZAR LA COMUNICACIÓN CENTRADA EN EL PACIENTE Y LA COLABORACIÓN MEDIANTE EL USO DE LA HISTORIA CLÍNICA ELECTRÓNICA EN LA SALA DE EXPLORACIONES

 

Thomsen M, Ingebrigtsen TS, Marott JL, Dahl M, Lange P, Vestbo J, et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. JAMA. 2013; 309:2353-2361 [S,I]

23757083             R/C

BIOMARCADORES INFLAMATORIOS Y EXACERBACIONES DE LA EPOC

 

Mador MJ, Sethi S. Systemic inflammation in predicting COPD exacerbations. JAMA. 2013; 309:2390-2391 [AO,I]

23757089

INFLAMACIÓN SISTÉMICA PARA PREDECIR LAS EXACERBACIONES DE LA EPOC

 

Krogsbøll LT, Jørgensen KJ, Gøtzsche PC. General health checks in adults for reducing morbidity and mortality from disease. JAMA. 2013; 309:2489-2490 [R,I]

23780462             R/C

PRUEBAS DE SALUD GENERALES EN ADULTOS PARA REDUCIR LA MORBILIDAD Y LA MORTALIDAD POR ENFERMEDAD

 

Sox HC. The health checkup: was it ever effective? Could it be effective? JAMA. 2013; 309:2496-2497 [AO,I]

23780465

LA PRUEBA DE SALUD: ¿FUÉ ALGUNA VEZ EFECTIVA? ¿PODRÍA SER EFECTIVA?

 

Marmot MG. Sorting through the arguments on breast screening. JAMA. 2013; 309:2553-2554 [AO,I]

23722915

SORTEAR A TRAVÉS DE LOS ARGUMENTOS SOBRE EL CRIBAJE DE CÁNCER DE MAMA

 

Kachalia A, Mello MM. Breast cancer screening: conflicting guidelines and medicolegal risk. JAMA. 2013; 309:2555-2556 [AO,I]

23722969

CRIBAJE DEL CÁNCER DE MAMA: PAUTAS CONFLICTIVAS Y RIESGO MEDICOLEGAL

 

Goldberger JJ, Buxton AE. Personalized medicine vs guideline-based medicine. JAMA. 2013; 309:2559-2560 [AO,I]

23712449

MEDICINA PERSONALIZADA FRENTE A MEDICINA BASADA EN LAS GUÍAS

 

Pasche B. Differential effects of aspirin before and after diagnosis of colorectal cancer. JAMA. 2013; 309:2598-2599 [AO,I]

23800937

EFECTOS DIFERENCIALES DE LA ASPIRINA ANTES Y DESPUÉS DEL DIAGNÓSTICO DE CÁNCER COLORRECTAL

 

Katz MH. Can we stop ordering prostate-specific antigen screening tests? JAMA Intern Med. 2013; 173:847-848 [AO,I]

23588841

¿PODEMOS DEJAR DE PEDIR ANÁLISIS DE PSA?

 

Morioka-Douglas N, Adams Hillard PJ. No papanicolaou tests in women younger than 21 years or after hysterectomy for benign disease. JAMA Intern Med. 2013; 173:855-856 [R,I]

23568165

NO PEDIR PRUEBAS DE PAPANICOLAU EN MUJERES DE MENOS DE 21 AÑOS O TRAS HISTERECTOMÍA POR ENFERMEDAD BENIGNA

 

Lefevre ML. Swimming upstream: doing less in health care is hard: comment on "no papanicolaou tests in women younger than 21 years or after hysterectomy for benign disease" and "cervical cancer screening intervals, 2006 to 2009". JAMA Intern Med. 2013; 173:856-858 [AO,I]

23568453

NADAR CONTRACORRIENTE: HACER MENOS EN LA ATENCIÓN SANITARIA ES DURO: COMENTARIO SOBRE "NO PEDIR PRUEBAS DE PAPANICOLAU EN MUJERES DE MENOS DE 21 AÑOS O TRAS HISTERECTOMÍA POR ENFERMEDAD BENIGNA"

 

Walter LC, Fung KZ, Kirby KA, Shi Y, Espaldon R, O'Brien S, et al. Five-year downstream outcomes following prostate-specific antigen screening in older men. JAMA Intern Med. 2013; 173:866-873 [S,I]

23588999             R/C

RESULTADOS DE 5 AÑOS DE CRIBAJE CON PSA EN ANCIANOS

 

Pitkälä KH, Pöysti MM, Laakkonen ML, Tilvis RS, Savikko N, Kautiainen H, et al. Effects of the Finnish Alzheimer Disease Exercise Trial (FINALEX): a randomized controlled trial. JAMA Intern Med. 2013; 173:894-901 [EC,II]

23589097             R/C

EFECTOS DEL ENSAYO FINALEX: ENSAYO CONTROLADO ALEATORIZADO

 

Clarfield AM, Dwolatzky T. Exercise in Alzheimer disease: comment on "Effects of the Finnish Alzheimer Disease Exercise Trial (FINALEX): a randomized controlled trial". JAMA Intern Med. 2013; 173:901-902 [AO,I]

23588877

EJERCICIO EN LA ENFERMEDAD DE ALZHEIMER: COMENTARIO SOBRE "EFECTOS DEL ENSAYO FINALEX: ENSAYO CONTROLADO ALEATORIZADO"

 

Monod S. Promoting good clinical care to prevent elder abuse: comment on "elder abuse as a risk factor for hospitalization in older persons". JAMA Intern Med. 2013; 173:917-918 [AO,I]

23568092

PROMOVER LA BUENA ATENCIÓN CLÍNICA PARA PREVENIR EL MALTRATO AL ANCIANO: COMENTARIO SOBRE "MALTRATO A LOS MAYORES COMO FACTOR DE RIESGO DE HOSPITALIZACIÓN EN ANCIANOS"

 

Heath I. Waste and harm in the treatment of mild hypertension. JAMA Intern Med. 2013; 173:956-957 [AO,I]

23699902

DESPILFARRO Y PERJUICIOS EN EL TRATAMIENTO DE LA HIPERTENSIÓN LIGERA

 

Puetz TW, Morley CA, Herring MP. Effects of creative arts therapies on psychological symptoms and quality of life in patients with cancer. JAMA Intern Med. 2013; 173:960-969 [M,II]

23699646             R/C

EFECTOS DE LAS TERAPIAS CON ARTES CREATIVAS SOBRE LOS SÍNTOMAS PSICOLÓGICOS Y LA CALIDAD DE VIDA EN PACIENTES CON CÁNCER

 

Bradt J, Goodill S. Creative arts therapies defined: comment on "effects of creative arts therapies on psychological symptoms and quality of life in patients with cancer". JAMA Intern Med. 2013; 173:969 [AO,I]

23699880

TERAPIAS CON ARTES CREATIVAS DEFINIDAS: COMENTARIO DE "EFECTOS DE LAS TERAPIAS CON ARTES CREATIVAS SOBRE LOS SÍNTOMAS PSICOLÓGICOS Y LA CALIDAD DE VIDA EN PACIENTES CON CÁNCER"

 

Doshi P. Influenza vaccines: time for a rethink. JAMA Intern Med. 2013; 173:1014-1016 [AO,I]

23553143             R/C

VACUNAS DE LA GRIPE: HORA DE VOLVER A PENSAR

 

Hardy J. Psychiatric genetics: are we there yet? JAMA Psychiatry. 2013; 70:569-570 [AO,I]

23571455

GENÉTICA PEDIÁTRICA: ¿ESTAMOS YA AHÍ?

 

Gutiérrez-Misis A, Sánchez-Santos MT, Banegas JR, Zunzunegui MV, Sánchez-Martínez M, Castell MV, et al. Asociación entre presión arterial y mortalidad en una cohorte de individuos de edad igual o superior a 65 años de España: un modelo dinámico. Rev Esp Cardiol. 2013; 66:464-471 [S,I]

23490258             R/C

ASOCIACIÓN ENTRE PRESIÓN ARTERIAL Y MORTALIDAD EN UNA COHORTE DE INDIVIDUOS DE EDAD IGUAL O SUPERIOR A 65 AÑOS DE ESPAÑA: UN MODELO DINÁMICO

 

Dégano IR, Elosua R, Marrugat J. Epidemiología del síndrome coronario agudo en España: estimación del número de casos y la tendencia de 2005 a 2049. Rev Esp Cardiol. 2013; 66:472-481 [T,I]

23664322             R/C

EPIDEMIOLOGÍA DEL SÍNDROME CORONARIO AGUDO EN ESPAÑA: ESTIMACIÓN DEL NÚMERO DE CASOS Y LA TENDENCIA DE 2005 A 2049

 

Kirkengen AL, Ekeland TJ, Getz L, Hetlevik I, Schei E, Ulvestad E, et al. What constitutes competence? That depends on the task. Scand J Prim Health Care. 2013; 31:65-66 [AO,I]

23659707

¿QUÉ CONSTITUYE LA COMPETENCIA? ESO DEPENDE DE LA TAREA

 

Skoglund I, Björkelund C, Petzold M, Gunnarsson R, Möller M. A randomized controlled trial comparing two ways of providing evidence-based drug information to GPs. Scand J Prim Health Care. 2013; 31:67-72 [EC,I]

23465039             R/C

ENSAYO CONTROLADO ALEATORIZADO COMPARANDO DOS FORMAS DE PROPORCIONAR INFORMACIÓN FARMACOLÓGICA BASADA EN LA EVIDENCIA A LOS MÉDICOS GENERALES

 

Bjornsson S, Sigurdsson JA, Svavarsdottir AE, Gudmundsson GH. Gatekeeping and referrals to cardiologists: general practitioners' views on interactive communications. Scand J Prim Health Care. 2013; 31:79-82 [T,I]

23607368             R/C

REGULACIÓN DE LA ENTRADA Y DERIVACIONES A LOS CARDIÓLOGOS: PUNTOS DE VISTA DE LOS MÉDICOS GENERALES SOBRE LAS COMUNICACIONES INTERACTIVAS

 

Zielinski A, Borgquist L, Halling A. Distance to hospital and socioeconomic status influence secondary health care use. Scand J Prim Health Care. 2013; 31:83-88 [T,I]

23301541             R/C

LA DISTANCIA AL HOSPITAL Y EL ESTATUS SOCIOECONÓMICO INFLUYEN SOBRE EL USO DE LA ATENCIÓN SANITARIA SECUNDARIA

 

Holmberg S, Thelin A. High dairy fat intake related to less central obesity: a male cohort study with 12 years' follow-up. Scand J Prim Health Care. 2013; 31:89-94 [S,I]

23320900             R/C

LA INGESTA ELEVADA DE GRASA LÁCTEA SE RELACIONA CON MENOS OBESIDAD CENTRAL: ESTUDIO DE COHORTE MASCULINA CON 12 AÑOS DE SEGUIMIENTO

 

Aamland A, Werner EL, Malterud K. Sickness absence, marginality, and medically unexplained physical symptoms: a focus-group study of patients' experiences. Scand J Prim Health Care. 2013; 31:95-100 [C,I]

23659708             R/C

AUSENCIA DE ENFERMEDAD, MARGINALIDAD Y SÍNTOMAS FÍSICOS SIN EXPLICACIÓN MÉDICA: ESTUDIO MEDIANTE GRUPO FOCAL DE LAS EXPERIENCIAS DE LOS PACIENTES

 

Andrés E, Cordero A, León M, Alcalde V, Laclaustra M, Casasnovas JA; en representación de los investigadores del estudio MESYAS (MEtabolic Syndrome Active Subjects). Escala para la predicción de la aparición de hipertensión arterial en población activa masculina. Med Clin (Barc). 2013; 140:487-492 [S,I]

23199830             R/C

ESCALA PARA LA PREDICCIÓN DE LA APARICIÓN DE HIPERTENSIÓN ARTERIAL EN POBLACIÓN ACTIVA MASCULINA

 

Pariente E, Ramos C, Olmos JM, Hernández JL, García P, Nan D. Relación entre la concentración plasmática de tirotropina y enfermedad cardiovascular (Cohorte Camargo). Med Clin (Barc). 2013; 140:493-499 [T,I]

22717352             R/C

RELACIÓN ENTRE LA CONCENTRACIÓN PLASMÁTICA DE TIROTROPINA Y ENFERMEDAD CARDIOVASCULAR (COHORTE CAMARGO)

 

Catalá-López F, Gènova-Maleras R. La prevención y el control de las enfermedades crónicas no transmisibles en España: una llamada para la acción. Med Clin (Barc). 2013; 140:502-503 [AO,I]

23294629

LA PREVENCIÓN Y EL CONTROL DE LAS ENFERMEDADES CRÓNICAS NO TRANSMISIBLES EN ESPAÑA: UNA LLAMADA PARA LA ACCIÓN

 

Piqué JM ¿Dónde está y hacia dónde va nuestro sistema sanitario?  Med Clin (Barc). 2013; 140:514-519 [AO,I]

23294630

¿DÓNDE ESTÁ Y HACIA DÓNDE VA NUESTRO SISTEMA SANITARIO?

 

Marshfield Clinic Research Foundation, Marshfield, Wisconsin. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013; 62(RR-04):1-34 [M,II]

23760231             R/C

PREVENCIÓN DEL SARAMPIÓN, LA RUBEOLA, EL SÍNDROME DE RUBEOLA CONGÉNITA Y LAS PAPERAS, 2013: RESUMEN DE LAS RECOMENDACIONES DEL ACIP

 

A revolution in psychiatry. Lancet. 2013; 381:1878 [AO,I]

23725715

UNA REVOLUCIÓN EN LA PSIQUIATRÍA

 

Ready, set, go for physical activity. Lancet. 2013; 381:1960 [AO,I]

23746881

PREPARADOS, LISTOS, YA PARA LA ACTIVIDAD FÍSICA

 

30 years of HIV: where next? Lancet. 2013; 381:2056 [AO,I]

23769214

30 AÑOS DE VIH: ¿DÓNDE ESTÁ LO SIGUIENTE?

 

Lewin SR. A cure for HIV: where we've been, and where we're headed. Lancet. 2013; 381:2057-2058 [AO,I]

23769215

CURA DEL VIH: DE DÓNDE VENIMOS, A DÓNDE NOS DIRIGIMOS

 

Karim SS. HIV pre-exposure prophylaxis in injecting drug users. Lancet. 2013; 381:2060-2062 [AO,I]

23769217

PROFILAXIS PREEXPOSICIÓN EN LOS USUARIOS DE DROGAS INYECTADAS

 

Violence against women: ending the global scourge. Lancet. 2013; 381:2135 [AO,I]

23791330

VIOLENCIA CONTRA LA MUJER: ACABAR CON EL AZOTE MUNDIAL

 

Steer PJ. Is vitamin D supplementation in pregnancy advisable? Lancet. 2013; 381:2143-2145 [AO,I]

23518315

¿SON ACONSEJABLES LOS SUPLEMENTOS DE VITAMINA D EN EL EMBARAZO?

 

Lawlor DA, Wills AK, Fraser A, Sayers A, Fraser WD, Tobias JH. Association of maternal vitamin D status during pregnancy with bone-mineral content in offspring: a prospective cohort study. Lancet. 2013; 381:2176-2183 [S,I]

23518316             R/C

ASOCIACIÓN DEL ESTATUS DE VITAMINA D MATERNA DURANTE EL EMBARAZO CON EL CONTENIDO MINERAL ÓSEO EN LA DESCENDENCIA: ESTUDIO PROSPECTIVO DE COHORTE

 

Piot P, Quinn TC. Response to the AIDS pandemic--a global health model. N Engl J Med. 2013; 368:2210-2218 [R,I]

23738546

RESPUESTA A LA PANDEMIA DE SIDA--UN MODELO MUNDIAL DE SALUD

 

Croskerry P. From mindless to mindful practice--cognitive bias and clinical decision making. N Engl J Med. 2013; 368:2445-2448 [AO,I]

23802513

DE LA PRÁCTICA SIN SENTIDO A LA PRÁCTICA CONSCIENTE--SESGO COGNITIVO Y TOMA DE DECISIONES CLÍNICAS

 

Smith AK, White DB, Arnold RM. Uncertainty--the other side of prognosis. N Engl J Med. 2013; 368:2448-2450 [AO,I]

23802514

INCERTIDUMBRE--LA OTRA CARA DEL PRONÓSTICO

 

Chen AH, Murphy EJ, Yee HF Jr. eReferral--a new model for integrated care. N Engl J Med. 2013; 368:2450-2453 [AO,I]

23802515

eDERIVACIÓN--UN NUEVO MODELO DE ATENCIÓN INTEGRADA

 

Wechsler ME. Inhibiting interleukin-4 and interleukin-13 in difficult-to-control asthma. N Engl J Med. 2013; 368:2511-2513 [AO,I]

23688322

INHIBICIÓN DE INTERLEUKINA 4 E INTERLEUKINA 13 EN EL ASMA DIFÍCIL DE CONTROLAR

 

Cates C. Inhaled corticosteroids in COPD: quantifying risks and benefits. Thorax. 2013; 68:499-500 [AO,I]

23242950

CORTICOIDES INHALADOS EN LA EPOC: CUANTIFICAR RIESGOS Y BENEFICIOS

 

Suissa S. Number needed to treat in COPD: exacerbations versus pneumonias. Thorax. 2013; 68:540-543 [M,II]

23125170             R/C

NÚMERO NECESARIO DE TRATAR EN EPOC: EXACERBACIONES FRENTE A NEUMONIAS

 

ACADEMIC MEDICINE

 

S23619078

 

In the last decade, electronic medical record (EMR) use in academic medical centers has increased. Although many have lauded the clinical and operational benefits of EMRs, few have considered the effect these systems have on medical education. The authors review what has been documented about the effect of EMR use on medical learners through the lens of the Accreditation Council for Graduate Medical Education's six core competencies for medical education. They examine acknowledged benefits and educational risks to use of EMRs, consider factors that promote their successful use when implemented in academic environments, and identify areas of future research and optimization of EMRs' role in medical education.

 

ANNALS OF INTERNAL MEDICINE

 

S23778904

 

In older adults, coprescription of clarithromycin or erythromycin with a statin that is metabolized by CYP3A4 increases the risk for statin toxicity.

S23732714

 

Many blood tests are moderately useful for identifying clinically significant fibrosis or cirrhosis in HCV-infected patients.

S23732715

 

The full guideline included 110 recommendations. This synopsis focuses on 10 key recommendations pertinent to definition, classification, monitoring, and management of CKD in adults.

S23732711

 

Regular sunscreen use retards skin aging in healthy, middle-aged men and women. No overall effect of ß-carotene on skin aging was identified, and further study is required to definitively exclude potential benefit or potential harm.

S23778903

 

The efficacy of rivaroxaban in VKA-experienced and VKA-naive patients was similar to that of the overall trial. There were more bleeding events within 7 days of study drug initiation with rivaroxaban, but after 30 days, rivaroxaban was associated with less bleeding in VKA-naive patients and similar bleeding in VKA-experienced patients. This information may be useful to clinicians considering a transition to rivaroxaban for patients receiving VKA therapy.

S23778902

 

Among these men, observation is more effective and costs less than initial treatment, and WW is most effective and least expensive under a wide range of clinical scenarios.

 

ARCHIVOS DE BRONCONEUMOLOGIA

 

S23317767

 

La EPOC está más infradiagnosticada en mujeres que en hombres en España.

S23477946

 

La implementación de la GPC SEMES-SEPAR 2008 con el uso del PSI y los biomarcadores mejoró de forma significativa todo el proceso asistencial de la NAC, siendo beneficiosa para los enfermos y para el sistema al lograr disminuir la mortalidad y el resto de indicadores de resultados y de manejo.

 

BRITISH MEDICAL JOURNAL

 

S23775799

 

Changes in global food prices will have a greater effect on food consumption in lower income countries and in poorer households within countries. This has important implications for national responses to increases in food prices and for the definition of policies designed to reduce the global burden of undernutrition.

S23778271

 

Men treated with 5-ARI for lower urinary tract symptoms had a decreased risk of cancer with Gleason scores 2-7, and showed no evidence of an increased risk of cancer with Gleason scores 8-10 after up to four years' treatment.

S23794316

 

Daily prenatal use of iron substantially improved birth weight in a linear dose-response fashion, probably leading to a reduction in risk of low birth weight. An improvement in prenatal mean haemoglobin concentration linearly increased birth weight.

S23661112

 

Under the base case scenario (using input parameters derived from the Independent Panel Review), there were 1521 fewer deaths from breast cancer and 2722 overdiagnosed breast cancers. Discounting future costs and benefits at a rate of 3.5% resulted in an additional 6907 person years of survival in the screened cohort, at a cost of 40? 946 additional years of survival after a diagnosis of breast cancer. Screening was associated with 2040 additional quality adjusted life years (QALYs) at an additional cost of £42.5m (€49.8m; $64.7m) in total or £20? 800 per QALY gained. The gain in person time survival over 35 years was 9.2 days per person and 2.7 quality adjusted days per person screened. Probabilistic sensitivity analysis showed that this incremental cost effectiveness ratio varied widely across a range of plausible scenarios. Screening was cost effective at a threshold of £20? 000 per QALY gained in 2260 (45%) scenarios, but in 588 (12%) scenarios, screening was associated with a reduction in QALYs. CONCLUSION: The NHS breast screening programme is only moderately likely to be cost effective at a standard threshold. However, there is substantial uncertainty in the model parameter estimates, and further primary research will be needed for cost effectiveness studies to provide definitive data to inform policy.

S23738992

 

Older adults with major depression in practices provided with additional resources to intensively manage depression had a mortality risk lower than that observed in usual care and similar to older adults without depression.

 

CANADIAN MEDICAL ASSOCIATION JOURNAL

 

S23670152

 

The risk of coronary artery disease was highest among participants who reported job strain and an unhealthy lifestyle; those with job strain and a healthy lifestyle had half the rate of disease. A healthy lifestyle may substantially reduce disease risk among people with job strain.

 

CIRCULATION

 

S23640971

 

The benefits of apixaban compared with warfarin for stroke or systemic embolism, bleeding, and mortality appear similar across the range of centers' and patients' predicted quality of international normalized ratio control.

S23658438

 

Atorvastatin plus etidronate combination therapy for 12 months significantly reduced both thoracic and abdominal aortic plaques, whereas atorvastatin monotherapy reduced only thoracic aortic plaques and etidronate monotherapy reduced only abdominal aortic plaques. The effectiveness of combination therapy in reducing atherosclerotic plaques in the abdominal aorta was significantly greater than for both atorvastatin and etidronate monotherapy.

 

DIABETES CARE

 

S23300287

 

Pregnant women with lower adiponectin levels at 1st trimester have higher levels of insulin resistance and are more likely to develop GDM independently of adiposity or glycemic measurements

S23275359

 

WC-mid is a better measurement to define central obesity than WC-IC, particularly in women.

S23275374

 

Along with glycemic control, nonophthalmologic manifestations of diabetes mellitus (e.g., nephropathy and nonhealing ulcers) are associated with an increased risk of diabetic retinopathy progression. Our retinopathy progression risk score can help clinicians stratify patients who are most at risk for disease progression.

S23300289

 

Lower CER was strongly associated with increased all-cause mortality in patients with type 2 diabetes and nephropathy. As the CER can be considered a proxy for muscle mass, this puts renewed emphasis on physical condition and exercise in this population.

S23315603

 

The findings suggest that, compared with younger adults, older adults receive equal glycemic benefit from participating in self-management interventions. Moreover, older adults showed the greatest glycemic improvement in the two group conditions. Clinicians can safely recommend group diabetes interventions to community-dwelling older adults with poor glycemic control.

 

DRUGS

 

S23677803

 

This article describes the mechanism of action, pharmacokinetics, and pharmacodynamics of aspirin at doses used for cardiovascular prevention and provides specific management recommendations for optimal use in clinical practice. The paper highlights practical aspects related to antiplatelet therapy, including the optimal dose of aspirin, concomitant treatment with other NSAIDs, and strategies for the prevention of gastrointestinal toxicity. Specifically, we revise the benefits and hazards in different clinical settings to help the clinician in the decision-making process for individuals who have different risks for cardiovascular and gastrointestinal bleeding events.

S23625272

 

While the majority of the RCTs have shown superior eradication rates with sequential therapy, the largest RCT from Latin America did not find a significant difference between the two treatment regimens. Sequential therapy has good efficacy; however, further trials other than those from Asia and Italy are required to assess its superiority over existing regimens before recommending sequential therapy as the first line of treatment for H. pylori infection.

S23677804

 

The direct factor Xa inhibitor apixaban (Eliquis(®)) has predictable pharmacodynamics and pharmacokinetics and does not require routine anticoagulation monitoring. This article reviews the efficacy and tolerability of oral apixaban to reduce the risk of stroke or systemic embolism in patients with nonvalvular atrial fibrillation (AF). In the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial in patients with AF and at least one additional risk factor for stroke, apixaban recipients were significantly less likely than warfarin recipients to experience stroke or systemic embolism, major bleeding or death; the beneficial effects of treatment with apixaban versus warfarin were generally maintained across various patient subgroups. Apixaban recipients also had a significantly lower risk of intracranial haemorrhage than warfarin recipients. In the AVERROES (Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients who have Failed or are Unsuitable for Vitamin K Antagonist Therapy) trial in patients with AF and at least one additional risk factor for stroke for whom vitamin K antagonist therapy was unsuitable, apixaban was associated with a significantly lower risk of stroke or systemic embolism than aspirin, without an increase in the risk of major bleeding. In conclusion, although longer-term efficacy and safety data are needed, apixaban is an important new option for use in patients with nonvalvular AF to reduce the risk of stroke or systemic embolism.

 

EUROPEAN HEART JOURNAL

 

S23509227

 

Dyslipidaemias play a key role in determining cardiovascular risk; the discovery of statins has contributed a very effective approach. However, many patients do not achieve, at the maximal tolerated dose, the recommended goals for low-density lipoprotein-cholesterol (LDL-C), non-high-density lipoprotein-cholesterol, and apolipoprotein B (apoB). Available agents combined with statins can provide additional LDL-C reduction, and agents in development will increase therapeutic options impacting also other atherogenic lipoprotein classes. In fact, genetic insights into mechanisms underlying regulation of LDL-C levels has expanded potential targets of drug therapy and led to the development of novel agents. Among them are modulators of apoB containing lipoproteins production and proprotein convertase subtilisin/kexin type-9 inhibitors. Alternative targets such as lipoprotein(a) also require attention; however, until we have a better understanding of these issues, further LDL-C lowering in high and very high-risk patients will represent the most sound clinical approach.

S23569199

 

On an empirical basis, exercise has been regarded as a fundamental pre-requisite for human well-being and physical integrity since classical times. Only in the last decades, however, scientific evidence has accumulated proving its role in the prevention and treatment of multiple chronic diseases beyond any reasonable doubt. Few treatment strategies in medicine have been tested so rigorously in large cohorts of patients as regular physical exercise. With the advent of molecular biology, the underlying mechanisms, such as NO bioavailability and mobilization of progenitor cells, could be identified. This enhances our understanding of this therapeutic tool. Unfortunately, the low compliance rate of the patients is the major drawback of the intervention exercise training (ET). The objective of this manuscript is to summarize the current knowledge with respect to ET on cardiovascular disease (CVD) and the molecular changes elicited by ET. Finally, we will critically assess reasons why ET as therapeutic option is not as effective at the population level in preventing CVD and what we may change in the future to make ET the most effective intervention to fight the development of CVD.

 

FAMILY MEDICINE

 

S23743938

 

The majority of respondents agreed that a baseline intern evaluation is useful; few are actually doing it. This area is not well-described in the literature; residency programs could benefit from information sharing. The next step is to encourage interest in and implementation of such strategies.

S23743941

 

We describe a longitudinal, practical, developmental, and clinically based experiential improvement curriculum that has been successfully integrated into a family medicine residency program.

 

FAMILY PRACTICE

 

S23315222

 

The identified trials included a range of case management interventions. Nine of the 11 trials showed no reduction of unplanned hospital admissions with case management compared with the same with usual care.

S23302818

 

The avoidance of NSAIDs in the medium term is unnecessary in patients with moderate to severe CKD, if not otherwise contraindicated. As the definition of high-dose of NSAID use remains unclear, the lowest effective dose of NSAIDs should be prescribed where indicated.

S23382502

 

Anticipatory cancer care from diagnosis to cure or death, 'in primary care', is feasible in the UK and acceptable to patients, although there are barriers. The process promoted continuity of care and holism. A reliable system for proactive cancer care in general practice supported by hospital specialists may allow more survivorship care to be delivered in primary care, as in other long-term conditions.

S23248235

 

Mortality in those with CKD is high, with non-cardiovascular diseases accounting for more than half of all deaths. While there is evidence that intervention may benefit those at risk of cardiovascular death, most of the non-cardiovascular causes of death identified were not readily amenable to prevention. A mechanism to identify which patients may benefit from intervention to prevent cardiovascular disease or renal disease progression is needed.

S23307818

 

This method provided a denominator that was reasonably similar to the enrolled population and was stable over time and by location, provider and practice characteristics. In regions without patient enrollment, this may provide an estimate of practice denominators.

S23132894

 

The frequency of medication errors is high in patients with polypharmacy in primary care. Development of strategies (e.g. external medication review) is required to counteract medication errors.

 

JOURNAL OF THE AMERICAN MECDIICAL ASSOCIATION

 

S23757083

 

Simultaneously elevated levels of CRP and fibrinogen and leukocyte count in individuals with COPD were associated with increased risk of having exacerbations, even in those with milder COPD and in those without previous exacerbations. Further investigation is needed to determine the clinical value of these biomarkers for risk stratification.

S23695200

 

In patients presenting to the emergency department with acute exacerbations of COPD, 5-day treatment with systemic glucocorticoids was noninferior to 14-day treatment with regard to reexacerbation within 6 months of follow-up but significantly reduced glucocorticoid exposure. These findings support the use of a 5-day glucocorticoid treatment in acute exacerbations of COPD.

S23780462

 

What are the benefits and harms of general health checks for adult populations? BOTTOM LINE: Compared with usual care, offers of health checks were not associated with lower rates of all-cause mortality, mortality from cardiovascular disease, or mortality from cancer. Health checks may be associated with more diagnoses and more drug treatment. Morbidity was infrequently reported, as were most harms, such as use of diagnostic procedures.

 

JAMA Internal Medicine

 

S23588999

 

Performance of prostate biopsy is uncommon in older men with abnormal screening PSA levels and decreases with advancing age and worsening comorbidity. However, once cancer is detected on biopsy, most men undergo immediate treatment regardless of advancing age, worsening comorbidity, or low-risk cancer. Understanding downstream outcomes in clinical practice should better inform individualized decisions among older men considering PSA screening.

S23553143

 

Officials and professional societies treat influenza as a major public health threat for which the annual vaccine offers a safe and effective solution. In this article, I challenge these basic assumptions. I show that there is no good evidence that vaccines reduce serious complications of influenza, the outcomes the policy is meant to address. Moreover, promotional messages conflate "influenza" (disease caused by influenza viruses) with "flu" (a syndrome with many causes, of which influenza viruses appear to be a minor contributor). This lack of precision causes physicians and potential vaccine recipients to have unrealistic assumptions about the vaccine's potential benefit, and impedes dissemination of the evidence on nonpharmaceutical interventions against respiratory diseases. In addition, there are potential vaccine-related harms, as unexpected and serious adverse effects of influenza vaccines have occurred. I argue that decisions surrounding influenza vaccines need to include a discussion of these risks and benefits.

S23699646

 

Exposure to CAT can improve anxiety, depression, and pain symptoms and QOL among cancer patients, but this effect is reduced during follow-up.

S23589097

 

An intensive and long-term exercise program had beneficial effects on the physical functioning of patients with AD without increasing the total costs of health and social services or causing any significant adverse effects

 

THE LANCET

 

S23518316

 

We found no relevant association between maternal vitamin D status in pregnancy and offspring BMC in late childhood.

 

MEDICINA CLINICA

 

S23199830

La progresión de la PA desde la normotensión a la hipertensión en los siguientes 7 años en varones jóvenes es alta y se puede estimar con una simple escala de riesgo.

S22717352

 

Se observa una asociación positiva entre la TSHp y ECV en varones=55 años y en mujeres=75 años. La combinación de la regresión múltiple y el análisis estratificado ha mostrado la compleja influencia de la edad en la relación entre ambas variables.

 

MORBIDITY AND MORTALITY WEEKLY REPORT

 

S23760231

 

This report is a compendium of all current recommendations for the prevention of measles, rubella, congenital rubella syndrome (CRS), and mumps. The report presents the recent revisions adopted by the Advisory Committee on Immunization Practices (ACIP) on October 24, 2012, and also summarizes all existing ACIP recommendations that have been published previously during 1998-2011 (CDC. Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices [ACIP]. MMWR 1998;47[No. RR-8]; CDC. Revised ACIP recommendation for avoiding pregnancy after receiving a rubellacontaining vaccine. MMWR 2001;50:1117; CDC. Updated recommendations of the Advisory Committee on Immunization Practices [ACIP] for the control and elimination of mumps. MMWR 2006;55:629-30; and, CDC. Immunization of healthcare personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2011;60[No. RR-7]). Currently, ACIP recommends 2 doses of MMR vaccine routinely for children with the first dose administered at age 12 through 15 months and the second dose administered at age 4 through 6 years before school entry. Two doses are recommended for adults at high risk for exposure and transmission (e.g., students attending colleges or other post-high school educational institutions, healthcare personnel, and international travelers) and 1 dose for other adults aged =18 years. For prevention of rubella, 1 dose of MMR vaccine is recommended for persons aged =12 months. At the October 24, 2012 meeting, ACIP adopted the following revisions, which are published here for the first time. These included: • For acceptable evidence of immunity, removing documentation of physician diagnosed disease as an acceptable criterion for evidence of immunity for measles and mumps, and including laboratory confirmation of disease as a criterion for acceptable evidence of immunity for measles, rubella, and mumps. • For persons with human immunodeficiency virus (HIV) infection, expanding recommendations for vaccination to all persons aged =12 months with HIV infection who do not have evidence of current severe immunosuppression; recommending revaccination of persons with perinatal HIV infection who were vaccinated before establishment of effective antiretroviral therapy (ART) with 2 appropriately spaced doses of MMR vaccine once effective ART has been established; and changing the recommended timing of the 2 doses of MMR vaccine for HIV-infected persons to age 12 through 15 months and 4 through 6 years. • For measles postexposure prophylaxis, expanding recommendations for use of immune globulin administered intramuscularly (IGIM) to include infants aged birth to 6 months exposed to measles; increasing the recommended dose of IGIM for immunocompetent persons; and recommending use of immune globulin administered intravenously (IGIV) for severely immunocompromised persons and pregnant women without evidence of measles immunity who are exposed to measles. As a compendium of all current recommendations for the prevention of measles, rubella, congenital rubella syndrome (CRS), and mumps, the information in this report is intended for use by clinicians as baseline guidance for scheduling of vaccinations for these conditions and considerations regarding vaccination of special populations. ACIP recommendations are reviewed periodically and are revised as indicated when new information becomes available.

 

REVISTA ESPAÑOLA DE CARDIOLOGIA

 

S23664322

 

El síndrome coronario agudo es una de las principales causas de mortalidad, morbilidad y coste sanitario en España. Los objetivos del presente estudio son estimar el número de casos de síndrome coronario agudo en España en 2013 y 2021, así como la tendencia en el periodo 2005¿2049. Se estimó el número de casos de síndrome coronario agudo según el sexo y la comunidad autónoma utilizando datos de los registros más actualizados. Se presenta el número de casos estimado y el intervalo de confianza exacto del 95% asumiendo una distribución de Poisson. En 2013 habrá unos 115.752 (intervalo de confianza del 95%, 114.822-116.687) casos de síndrome coronario agudo en España. De estos, 39.086 morirán durante los primeros 28 días y 85.326 serán hospitalizados. Los diagnósticos más comunes al ingreso y al alta serán síndrome coronario agudo sin elevación del ST (56%) e infarto agudo de miocardio (81%) respectivamente. En 2021 el número de casos de síndrome coronario agudo se situará en 109.772 (intervalo de confianza del 95%, 108.868-110.635). La tendencia en el número de casos de síndrome coronario agudo entre 2005 y 2049 tenderá a estabilizarse en la población de 25 a 74 años y aumentar significativamente en la población mayor de 74 años. Los casos de síndrome coronario agudo aumentarán hasta el año 2049 debido al envejecimiento de la población, aunque parece estabilizarse en la población menor de 75 años. La letalidad del síndrome coronario agudo entre los pacientes hospitalizados se ha reducido, pero la proporción de muertes súbitas se mantiene sin cambios.

S23490258

 

Teniendo en cuenta la relación dinámica entre la presión arterial y la mortalidad, nuestros datos muestran una relación en forma de U para la presión arterial sistólica y una relación negativa para la presión arterial diastólica y mortalidad por todas las causas. La menor mortalidad correspondió a un valor de presión arterial sistólica ligeramente superior al valor diagnóstico de hipertensión, lo que indica que 140 mmHg podría no ser adecuado como valor diagnóstico y objetivo terapéutico en la población anciana.

 

SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE

 

S23320900

 

A high intake of dairy fat was associated with a lower risk of central obesity and a low dairy fat intake was associated with a higher risk of central obesity.

S23659708

 

Confidence from both personal and professional contacts is crucial. GPs have an important and appreciated role in this aspect.

S23465039

 

This study could not prove that specially tailored EBDI using MI implements guidelines more effectively than EBDI provided as usual.

S23607368

 

A referral system increases the flow of information and mutual communications between general practitioners and specialists to the benefit of the patients. The geographical location of the health care centre may be of importance regarding the value of the referrals.

S23301541

 

It was found that distance to hospital and SES influence SHC use after adjusting for comorbidity level, age, and gender. These results suggest that GPs and health care managers should pay a higher degree of attention to this when planning primary care services in order to minimize the potentially redundant use of SHC.

 

THORAX

 

S23125170

 

The NNT is a useful measure of the effect of drugs, but its proper calculation is essential to prevent misleading clinical practice guidelines.

 

 

 

 

 

 

 

                      

XXVIII Congreso de Comunicación y Salud

 

 

semFYC - JRT 2017

 

Cáceres, 10 y 11 de Noviembre 2017


____________________________

 Para pacientes
@pontealdiaAP
 @pontealdiaURG
55 e.SAMFyC

 


 

semFYC
 

 

Estadisticas

Ver contenido por hits : 1101574



La SAMFyC:
 C/ Arriola, 4, bajo D, CP.18001 - Granada. Email: samfyc@samfyc.es; Teléfono: 958 804 201 - Fax: 958 804 202. Horario de invierno: lunes a jueves de 9:00 a 17:30 horas; viernes de 9:00 a 14:30 horas. Horario de verano: lunes a viernes de 8:00 a 15:00h. Todos los derechos reservados. Aviso Legal. 


¡CSS Válido!

Diseño web